Preventing the broad spectrum of perinatal morbidity and mortality through group B streptococcal vaccination

Vaccine. 2013 Aug 28;31 Suppl 4:D66-71. doi: 10.1016/j.vaccine.2012.11.046. Epub 2012 Nov 28.


The development of a group B streptococcal (GBS) glycoconjugate vaccine and its upcoming evaluation in a phase 3 trial in pregnant women highlight the importance of defining the anticipated impact of GBS vaccination upon the broad spectrum of GBS-related perinatal morbidity and mortality. We present the specific pregnancy-associated and neonatal conditions attributable, at least in part, to GBS in high and lower income countries. We offer a rationale to support our contention that implementation of GBS glycoconjugate immunization during pregnancy will reduce the global burden of GBS-related morbidity and mortality in pregnant women and their infants.

Keywords: CDC; CPS; Centers for Disease Control and Prevention; GBS; Group B Streptococcus; IAI; Morbidity; PROM; Perinatal; Pregnancy; Prevention; Vaccine; capsular polysaccharide; group B Streptococcus; intra-amniotic infection; premature rupture of membranes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Humans
  • Infant, Newborn
  • Infant, Newborn, Diseases / microbiology
  • Infant, Newborn, Diseases / mortality
  • Infant, Newborn, Diseases / prevention & control*
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Pregnancy
  • Pregnancy Complications, Infectious / prevention & control
  • Streptococcal Infections / microbiology
  • Streptococcal Infections / mortality
  • Streptococcal Infections / prevention & control*
  • Streptococcal Vaccines / therapeutic use*
  • Streptococcus agalactiae
  • United Kingdom
  • United States
  • Vaccination
  • Vaccines, Conjugate / therapeutic use


  • Streptococcal Vaccines
  • Vaccines, Conjugate